Tanja Obradovic summarizes the latest news on immunotherapy with chemoradiation NSCLC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at
“Based on what we found yesterday and negative read out of the progression-free survival (PFS) primary end-point of Phase 3 CheckMate73L trial (NCT04026412) adding even more immunotherapy to chemoradiotherapy does not result in better outcome in patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC) (link to announcement below).
Treatment with Nivolumab (Opdivo) plus concurrent chemoradiotherapy, followed by the combination of Nivolumab and Ipilimumab (Yervoy) did not improve PFS vs chemoradiotherapy followed by Durvalumab (Imfinzi) monotherapy.
Based on PACIFIC trial (NCT02125461) treatment with Durvalumab of stage III unresectable, locally advanced NSCLC patients who have not progressed following definitive, platinum-based, concurrent chemoradiotherapy is a current standard of care approved by FDA in 2018.
Once detailed results of CheckMate73L are known it will be of interest to see magnitude of difference as well as patient disposition that can provide insights into how well tolerated was treatment with Nivolumab plus chemoradiation as well as Nivolumab combo with Ipilimumab.
In addition, to note that populations eligible for CheckMate73L included stage IIIA, IIIB, or IIIC NSCLC patients while PACIFIC population with reported results was IIIA and IIIB NSCLC patients.
(link to publication of PACIFIC trial update on 5-year survival) .”
Source: Tanja Obradovic/LinkedIn